간 외 전이가 있는 간세포암종 환자에서 경동맥화학색전술 = Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Extrahepatic Metastasis

다국어 초록 (Multilingual Abstract)

Transarterial chemoembolization (TACE) has been widely performed as a treatment for unresectable hepatocellular carcinoma (HCC). Recently extrahepatic metastasis (EHM) of HCC is increasing due to improvement of survival. Sorafenib has been generally accepted as a standard treatment in advanced HCC. However, many HCC patients with EHM are treated with TACE in real-world clinical practice because sorafenib has modest efficacy and the main cause of death in the patients with EHM is hepatic failure. In this review, the usefulness of TACE for the patients with HCC and EHM will be discussed.

참고문헌 (Reference)

1 천재희, "단일 기관에서 치료한 간세포암종 1,078예의 임상 백서" 대한간학회 10 (10): 288-297, 2004

2 Zhao Y, "Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: a systematic review" 9 : 357-364, 2013

3 Cammà C, "Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials" 224 : 47-54, 2002

4 Park KW, "Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area" 23 : 467-473, 2008

5 Llovet JM, "Sorafenib in advanced hepatocellular carcinoma" 359 : 378-390, 2008

6 Wang G, "Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review" 10 : 501-510, 2016

7 Choi GH, "Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses" 269 : 603-611, 2013

8 Jung SM, "Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases" 27 : 684-689, 2012

9 Wu H, "Pure transcatheter arterial chemoembolization therapy for intrahepatic tumors causes a shrink in pulmonary metastases of hepatocellular carcinoma" 8 : 1035-1042, 2015

10 Okusaka T, "Prognosis of heaptocellular carcinoma patients with extrahepatic metastases" 44 : 251-257, 1997

11 Bruix J, "Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma" 42 : 1208-1236, 2005

12 Yau T, "Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population:presence of lung metastasis predicts poor response" 115 : 428-436, 2009

13 Nakashima T, "Pathology of hepatocellular carcinoma in Japan. 232 Consecutive cases autopsied in ten years" 51 : 863-877, 1983

14 Lee HS, "Management of patients with hepatocellular carcinoma and extrahepatic metastasis" 29 : 333-338, 2011

15 Kudo M, "Management of hepatocellular carcinoma in Japan:Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version" 29 : 339-364, 2011

16 Kanda M, "Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors" 28 : 1256-1263, 2008

17 Katyal S, "Extrahepatic metastases of hepatocellular carcinoma" 216 : 698-703, 2000

18 Senthilnathan S, "Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies:analyzing patterns of progression in 285 patients" 55 : 1432-1442, 2012

19 Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial" 10 : 25-34, 2009

20 Yoo JJ, "Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases" 9 : e113926-, 2014

21 Yoo DJ, "Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?" 26 : 145-154, 2011

22 Natsuizaka M, "Clinical features of hepatocellular carcinoma with extrahepatic metastases" 20 : 1781-1787, 2005

23 Uka K, "Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma" 13 : 414-420, 2007

24 Attili VS, "Bone metastasis in hepatocellular carcinoma: need for reappraisal of treatment" 4 : 93-94, 2008

25 Llovet JM, "Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial" 359 : 1734-1739, 2002

26 Yamakado K, "Adrenal metastasis from hepatocellular carcinoma: radiofrequency ablation combined with adrenal arterial chemoembolization in six patients" 192 : W300-W305, 2009

27 한국 간 암 스터디그룹, "2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma" 거트앤리버 발행위원회 9 (9): 267-317, 2015